3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
9
Colorectal Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumor
2
Triple Negative Breast Neoplasms
1
Solid Cancer
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Astrocytoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Temozolomide
26
Radiotherapy
10
Bevacizumab
10
Carboplatin
6
Irinotecan
5
pembrolizumab
4
Radiation
4
Nivolumab
4
IL13-PE38
4
temsirolimus
3
Surgical Procedures, Operative
3
Magnetic Resonance Spectroscopy
3
Immunotherapy, Adoptive
3
Erlotinib Hydrochloride
3
Aminolevulinic Acid
3
trametinib
2
olaparib
2
lutetium Lu 177 dotatate
2
fludarabine
2
dabrafenib
2
cemiplimab
2
abemaciclib
2
Vorinostat
2
Transurethral Resection of Bladder
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
Imatinib Mesylate
2
Flucytosine
2
Cyclophosphamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled